{"id":"NCT03015610","sponsor":"Jason Lang, M.D., M.P.H.","briefTitle":"Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma","officialTitle":"Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-31","primaryCompletion":"2024-01-18","completion":"2024-01-18","firstPosted":"2017-01-10","resultsPosted":"2025-09-09","lastUpdate":"2025-09-09"},"enrollment":41,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma","Gastroesophageal Reflux"],"interventions":[{"type":"DRUG","name":"commercially available lansoprazole","otherNames":["once daily"]},{"type":"DRUG","name":"matched placebo","otherNames":["once daily"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Genotype-guided Lansoprazole","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the effect of CYP2C19 and ABCB1 genes on pharmacokinetics of lansoprazole in children with mild gastroesophageal reflux (GER) and uncontrolled asthma. It will determine if genotype-guided lansoprazole dosing of lansoprazole improves GER and asthma control.","primaryOutcome":{"measure":"Change in Asthma Control Questionnaire (ACQ) From Screening Through Week 26","timeFrame":"Week 0 (baseline) to week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.5,"sd":0.5},{"arm":"Genotype-guided Lansoprazole","deltaMin":-0.6,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8716"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":["Headaches","Flatulence","Nausea","Diarrhea","Constipation"]}}